Most Recent Articles by Da Hee Han, PharmD
Patients with type 2 diabetes who received once-weekly semaglutide had statistically greater reductions in HbA1c and body weight compared with those treated with dulaglutide.
Two recently-approved diabetes treatments, a semaglutide injection and an insuline aspart injection, are now available in pharmacies across the United States.
The FDA has approved Zomacton, a somatropin injection, for the replacement of growth hormone in adults with GH deficiency.
The initial decision to discontinue Tanzeum was announced in August 2017 due to limited prescribing of the drug and not because of safety concerns.
Novo Nordisk has announced that the NovoFine 30G 8mm pen needle will be discontinued on or before April 30, 2018.
More Articles by Da Hee Han, PharmD
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis